At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
OPC-1085EL ophthalmic solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers
In Brief
A Phase 1 clinical trial evaluating OPC-1085EL ophthalmic solution, Carteolol long-acting ophthalmic solution, and 1 other intervention for Glaucoma and Ocular Hypertension. Completed, enrolled 30 participants across 1 site.
Detailed Summary
OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteolol and latanoprost in OPC-1085EL ophthalmic solution by formulating the combination drug will be determined.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedApr 2014
Primary CompletionMay 2014
Study CompletionAug 2014
TodayJul 2026
First PostedApr 9, 2014
Enrollment StartApr 1, 2014
Primary CompletionMay 1, 2014
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 12.2 years ago
Interventions
OPC-1085EL ophthalmic solutiondrug
Carteolol long-acting ophthalmic solutiondrug
Latanoprost ophthalmic solutiondrug